Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.

<h4>Aim</h4>To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results.<h4&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian-Hong Zhong, Xin-Shao Mo, Bang-De Xiang, Wei-Ping Yuan, Jin-Fang Jiang, Gui-Sheng Xie, Le-Qun Li
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d68bf9e1c45f430bac18b6bbf9b63b4b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d68bf9e1c45f430bac18b6bbf9b63b4b
record_format	dspace
spelling	oai:doaj.org-article:d68bf9e1c45f430bac18b6bbf9b63b4b2021-11-18T07:54:25ZPostoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.1932-620310.1371/journal.pone.0058082https://doaj.org/article/d68bf9e1c45f430bac18b6bbf9b63b4b2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23505456/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aim</h4>To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results.<h4>Methods</h4>MEDLINE, EMBASE and Cochrane library databases were systematically searched through the end of May 2012. Meta-analysis of RCTs and cohort studies was performed to estimate the effects of the VK2 analog on tumor recurrence rate and overall survival (OS). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated.<h4>Results</h4>Six RCTs and one cohort study involving a total of 930 patients were included. VK2 analog therapy did not reduce the 1-year recurrence rate, with a pooled RR of 0.67 (95% CI 0.39-1.13, p = 0.13). However, VK2 analog therapy was associated with a significant reduction in the 2- and 3-year tumor recurrence rates, with respective pooled RRs of 0.65 (95% CI 0.51-0.83, p<0.001) and 0.70 (95% CI = 0.58-0.85, p<0.001). The therapy was also associated with a significant improvement in 1-, 2-, and 3-year OS, with respective pooled RRs of 1.03 (95% CI 1.01-1.05, p = 0.02), 1.11 (95% CI 1.03-1.19, p = 0.005) and 1.14 (95% CI 1.02-1.28, p = 0.02). None of the studies reported adverse effects attributable to VK2 analog therapy.<h4>Conclusion</h4>The VK2 analog may reduce recurrence rate after 1 year and improve OS in HCC patients as early as 1 year. However, these findings should be considered preliminary since the majority of patients came from an RCT with survival data out to only 1 year. More extensive studies with larger sample sizes and longer follow-up are needed.Jian-Hong ZhongXin-Shao MoBang-De XiangWei-Ping YuanJin-Fang JiangGui-Sheng XieLe-Qun LiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e58082 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jian-Hong Zhong Xin-Shao Mo Bang-De Xiang Wei-Ping Yuan Jin-Fang Jiang Gui-Sheng Xie Le-Qun Li Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
description	<h4>Aim</h4>To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results.<h4>Methods</h4>MEDLINE, EMBASE and Cochrane library databases were systematically searched through the end of May 2012. Meta-analysis of RCTs and cohort studies was performed to estimate the effects of the VK2 analog on tumor recurrence rate and overall survival (OS). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated.<h4>Results</h4>Six RCTs and one cohort study involving a total of 930 patients were included. VK2 analog therapy did not reduce the 1-year recurrence rate, with a pooled RR of 0.67 (95% CI 0.39-1.13, p = 0.13). However, VK2 analog therapy was associated with a significant reduction in the 2- and 3-year tumor recurrence rates, with respective pooled RRs of 0.65 (95% CI 0.51-0.83, p<0.001) and 0.70 (95% CI = 0.58-0.85, p<0.001). The therapy was also associated with a significant improvement in 1-, 2-, and 3-year OS, with respective pooled RRs of 1.03 (95% CI 1.01-1.05, p = 0.02), 1.11 (95% CI 1.03-1.19, p = 0.005) and 1.14 (95% CI 1.02-1.28, p = 0.02). None of the studies reported adverse effects attributable to VK2 analog therapy.<h4>Conclusion</h4>The VK2 analog may reduce recurrence rate after 1 year and improve OS in HCC patients as early as 1 year. However, these findings should be considered preliminary since the majority of patients came from an RCT with survival data out to only 1 year. More extensive studies with larger sample sizes and longer follow-up are needed.
format	article
author	Jian-Hong Zhong Xin-Shao Mo Bang-De Xiang Wei-Ping Yuan Jin-Fang Jiang Gui-Sheng Xie Le-Qun Li
author_facet	Jian-Hong Zhong Xin-Shao Mo Bang-De Xiang Wei-Ping Yuan Jin-Fang Jiang Gui-Sheng Xie Le-Qun Li
author_sort	Jian-Hong Zhong
title	Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
title_short	Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
title_full	Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
title_fullStr	Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
title_full_unstemmed	Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
title_sort	postoperative use of the chemopreventive vitamin k2 analog in patients with hepatocellular carcinoma.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/d68bf9e1c45f430bac18b6bbf9b63b4b
work_keys_str_mv	AT jianhongzhong postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT xinshaomo postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT bangdexiang postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT weipingyuan postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT jinfangjiang postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT guishengxie postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT lequnli postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma
_version_	1718422797706854400

Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.

Ejemplares similares